Heron Therapeutics, Inc. (0J4V.L)
USD 1.92
(4.92%)
USD 1.92
(4.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -110.61 Million USD | 34.65% |
| 2022 | -169.25 Million USD | 21.72% |
| 2021 | -216.22 Million USD | 5.23% |
| 2020 | -228.16 Million USD | -8.29% |
| 2019 | -210.69 Million USD | -14.55% |
| 2018 | -183.93 Million USD | 4.58% |
| 2017 | -192.75 Million USD | -18.17% |
| 2016 | -163.11 Million USD | -68.29% |
| 2015 | -96.92 Million USD | -29.99% |
| 2014 | -74.56 Million USD | -36.92% |
| 2013 | -54.45 Million USD | -128.51% |
| 2012 | -23.83 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.79 Million USD | 53.05% |
| 2024 Q2 | -6.44 Million USD | -34.33% |
| 2023 Q1 | -33.06 Million USD | -62.43% |
| 2023 Q3 | -24.92 Million USD | 41.21% |
| 2023 Q4 | -10.22 Million USD | 59.0% |
| 2023 FY | -110.61 Million USD | 34.65% |
| 2023 Q2 | -42.4 Million USD | -28.25% |
| 2022 FY | -169.25 Million USD | 21.72% |
| 2022 Q3 | -41.88 Million USD | 15.39% |
| 2022 Q2 | -49.49 Million USD | 21.34% |
| 2022 Q1 | -62.92 Million USD | -21.15% |
| 2022 Q4 | -20.35 Million USD | 51.4% |
| 2021 Q4 | -51.93 Million USD | -0.44% |
| 2021 Q2 | -60.46 Million USD | -16.03% |
| 2021 Q3 | -51.7 Million USD | 14.49% |
| 2021 FY | -216.22 Million USD | 5.23% |
| 2021 Q1 | -52.11 Million USD | 6.43% |
| 2020 Q3 | -58.38 Million USD | -4.73% |
| 2020 Q4 | -55.69 Million USD | 4.6% |
| 2020 FY | -228.16 Million USD | -8.29% |
| 2020 Q1 | -52.73 Million USD | -3.48% |
| 2020 Q2 | -55.74 Million USD | -5.72% |
| 2019 Q1 | -64.7 Million USD | -32.0% |
| 2019 Q2 | -51.77 Million USD | 19.97% |
| 2019 Q4 | -50.96 Million USD | -46.22% |
| 2019 FY | -210.69 Million USD | -14.55% |
| 2019 Q3 | -34.85 Million USD | 32.69% |
| 2018 FY | -183.93 Million USD | 4.58% |
| 2018 Q4 | -49.01 Million USD | -17.31% |
| 2018 Q3 | -41.78 Million USD | -7.53% |
| 2018 Q2 | -38.85 Million USD | 25.27% |
| 2018 Q1 | -51.99 Million USD | 16.0% |
| 2017 FY | -192.75 Million USD | -18.17% |
| 2017 Q2 | -42.05 Million USD | 14.69% |
| 2017 Q3 | -41.31 Million USD | 1.76% |
| 2017 Q4 | -61.89 Million USD | -49.8% |
| 2017 Q1 | -49.29 Million USD | -15.45% |
| 2016 Q3 | -47.73 Million USD | -10.84% |
| 2016 FY | -163.11 Million USD | -68.29% |
| 2016 Q2 | -43.06 Million USD | -29.28% |
| 2016 Q1 | -33.31 Million USD | -7.25% |
| 2016 Q4 | -42.7 Million USD | 10.54% |
| 2015 FY | -96.92 Million USD | -29.99% |
| 2015 Q4 | -31.06 Million USD | -38.1% |
| 2015 Q1 | -20.36 Million USD | -4.44% |
| 2015 Q3 | -22.49 Million USD | 2.27% |
| 2015 Q2 | -23.01 Million USD | -13.04% |
| 2014 Q2 | -18.79 Million USD | -8.48% |
| 2014 Q3 | -18.95 Million USD | -0.86% |
| 2014 FY | -74.56 Million USD | -36.92% |
| 2014 Q1 | -17.32 Million USD | -25.24% |
| 2014 Q4 | -19.49 Million USD | -2.86% |
| 2013 FY | -54.45 Million USD | -128.51% |
| 2013 Q4 | -13.83 Million USD | -9.22% |
| 2013 Q1 | -12.75 Million USD | -47.8% |
| 2013 Q3 | -12.66 Million USD | 16.73% |
| 2013 Q2 | -15.2 Million USD | -19.27% |
| 2012 Q4 | -8.62 Million USD | 0.0% |
| 2012 FY | -23.83 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.613% |
| Dynavax Technologies Corporation | -37.02 Million USD | -198.733% |
| Illumina, Inc. | -1.06 Billion USD | 89.652% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 105.595% |
| Biogen Inc. | 1.29 Billion USD | 108.53% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 75.982% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 110.174% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 58.699% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1999.355% |
| Waters Corporation | 817.67 Million USD | 113.528% |
| Perrigo Company plc | 151.9 Million USD | 172.821% |
| uniQure N.V. | -282.87 Million USD | 60.896% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 71.745% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -50.509% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 59.923% |
| bluebird bio, Inc. | -244.26 Million USD | 54.715% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 8.955% |
| Imunon, Inc. | -21.03 Million USD | -425.976% |
| Myriad Genetics, Inc. | -123.7 Million USD | 10.578% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 144.087% |
| Nektar Therapeutics | -137.42 Million USD | 19.509% |
| Editas Medicine, Inc. | -169.18 Million USD | 34.617% |
| Verastem, Inc. | -92.08 Million USD | -20.124% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.214% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -145.39% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -147.644% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 156.889% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 59.63% |
| Evolus, Inc. | -49.23 Million USD | -124.677% |
| Adicet Bio, Inc. | -152.03 Million USD | 27.245% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -13.618% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.733% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 28.894% |
| FibroGen, Inc. | -281.81 Million USD | 60.749% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 108.194% |
| OPKO Health, Inc. | -157.02 Million USD | 29.554% |
| Homology Medicines, Inc. | -48.25 Million USD | -129.23% |
| Geron Corporation | -193.94 Million USD | 42.965% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 60.799% |
| Exelixis, Inc. | 170.88 Million USD | 164.731% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -9.708% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -98.391% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 78.533% |
| Zoetis Inc. | 3.06 Billion USD | 103.604% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 52.285% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -129.492% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.568% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -182.52% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 68.729% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 203.107% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 132.768% |
| Blueprint Medicines Corporation | -486.27 Million USD | 77.253% |
| Insmed Incorporated | -709.62 Million USD | 84.412% |
| TG Therapeutics, Inc. | 20.63 Million USD | 636.107% |
| Incyte Corporation | 620.52 Million USD | 117.826% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 84.772% |